Spica Therapeutics

Explore Spica Therapeutics’ CD163 therapeutic pipeline targeting disease-driving macrophages in solid tumors and fibrosis, with biomarker-driven patient selection.

The page describes Spica Therapeutics’ Macrophage Fingerprinting Platform, which identifies macrophage targets in specific patient populations for various diseases, including oncology, fibrosis, and neurodegeneration.

Bioqube Ventures unveils Spica Therapeutics, a biotech developing precision therapies that selectively target disease-relevant macrophage subsets.

Spica Therapeutics nominates ST101 as its first clinical development candidate to overcome resistance in first-line solid tumor indications.

Spica Therapeutics introduces its leadership and scientific team, which specializes in macrophage biology, therapeutic antibodies, and drug development.

Discover Spica Therapeutics, a biotechnology company developing antibody-based therapies through precision targeting of disease-driving macrophages.

Spica Therapeutics develops precision therapies that selectively target disease-driving macrophage subsets in oncology, fibrosis and chronic diseases.

Spica Therapeutics names Jeff Abbey as its new CEO. Abbey previously led RNatives as CEO and now serves as Chairman of the Board there. The appointment marks a leadership transition for the biotech company.

Oct 2026PM LiVENews article

Spica Therapeutics names Jeff Abbey as its new Chief Executive Officer. Abbey brings over two decades of experience in life sciences leadership, including biotech company building, corporate development, and capital formation. The appointment supports Spica’s plan to expand its Macrophage Fingerprinting Platform into high-value chronic disease areas.

Oct 2026Bioqube VenturesNews article

ProBioGen is developing cell lines for Spica Therapeutics’ ST101, an anti-CD163 depleting antibody in oncology. The partnership supports Spica’s first clinical candidate, targeting immune-related therapies for cancer treatment. ProBioGen will provide critical cell line engineering services to advance ST101 into clinical trials.

Dec 2025SelectScienceNews article

Spica Therapeutics receives a **€1 million grant from VLAIO** to develop macrophage-targeted cancer therapies. The biotech company specializes in leveraging macrophage biology for treatments across multiple diseases. The funding supports research into novel approaches targeting immune cells to combat cancer.

Aug 2025VIBNews article